Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Bempegaldesleukin with Chemoradiotherapy in Soft Tissue Sarcoma
NCT07156643Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and bempegaldesleukin in soft tissue sarcoma (STS), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 2 years. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
anlotinibbempegaldesleukin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07156643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156643.